E

Where’s the next exciting IO target coming from?

Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...

May 20, 2019
E

Challenges of targeting KRASG12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019
E

Can Silverback increase the Firepower of TLR agonists?

A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche

May 9, 2019
E

Targeting the adenosine pathway in cancer immunotherapy

A look a the updated adenosine pathway landscape and how it is progressing

April 18, 2019